Table 4.
Multiple Regression Analysis to Determine Variables Associated Responders of Switching to Teneligliptin
| OR | 95% CI | P value | |
|---|---|---|---|
| Age, year | 1.00 | 0.93–1.07 | 0.947 |
| Sex, male | 1.10 | 0.46–2.62 | 0.832 |
| Body mass index, kg/m2 | 0.99 | 0.87–1.13 | 0.927 |
| Duration of type 2 diabetes, year | 0.88 | 0.97–1.03 | 0.880 |
| Baseline HbA1c, % | 2.44 | 1.62–3.67 | <0.001 |
| Triglyceride, baseline, mg/dl* | 0.34 | 0.14–0.82 | 0.016 |
| LDL cholesterol, mg/dl* | 0.95 | 0.30–3.10 | 0.954 |
| CKD stage 3 or more | 0.97 | 0.41–2.59 | 0.929 |
| Lipid lowering agent use | 0.40 | 0.17–0.97 | 0.042 |
| Insulin use | 0.99 | 0.34–2.99 | 0.989 |
Note: *log-transformed.
Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; HbA1c, glycated hemoglobin A1c; LDL cholesterol, low-density lipoprotein cholesterol; CKD, chronic kidney disease.